Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jian-jun Li

Showing results (21-30 of 824) with videos related to

Pageof 83
Sort By:
Journal of Atherosclerosis and Thrombosis|November 21, 2014
PCSK9: A key factor modulating atherosclerosisSha Li, Jian-Jun Li
Clinics (Sao Paulo, Brazil)|October 22, 2013
Authors' comments on: Higher red cell distribution width in patients with slow coronary flowSong-Hui Luo, Jian-Jun Li
Medical Hypotheses|February 8, 2005
Should atherosclerosis be considered a cancer of the vascular wall?Jian-Jun Li, Run-Lin Gao
Diabetes Care|March 22, 2018
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367Ye-Xuan Cao, Jian-Jun Li
Medical Hypotheses|March 31, 2004
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseasesJian-Jun Li, Chun-Hong Fang
Chinese Medical Journal|March 28, 2009
Maximizing benefit of drug-eluting stent by direct coronary stenting because of further reduction of inflammatory responseJian-Jun Li, Run-Lin Gao
Science Bulletin|June 26, 2026
Lipoprotein(a): a therapeutic target in waiting? Evidently, evidence-basedRui-Xiang Zeng, Jian-Jun Li
Medical Hypotheses|June 15, 2004
Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosisJian-Jun Li, Chun-Hong Fang
Clinical Chemistry|August 27, 2005
Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable anginaJian-Jun Li, Chun-Hong Fang
Chronic Diseases and Translational Medicine|October 25, 2017
Clinical considerations of lipid target and goal in dyslipidemia controlNa-Qiong Wu, Jian-Jun Li
Pageof 83

Showing results (21-30 of 824) with videos related to

Sort By:
Pageof 83
Journal of Atherosclerosis and Thrombosis|November 21, 2014
PCSK9: A key factor modulating atherosclerosisSha Li, Jian-Jun Li
Clinics (Sao Paulo, Brazil)|October 22, 2013
Authors' comments on: Higher red cell distribution width in patients with slow coronary flowSong-Hui Luo, Jian-Jun Li
Medical Hypotheses|February 8, 2005
Should atherosclerosis be considered a cancer of the vascular wall?Jian-Jun Li, Run-Lin Gao
Diabetes Care|March 22, 2018
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367Ye-Xuan Cao, Jian-Jun Li
Medical Hypotheses|March 31, 2004
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseasesJian-Jun Li, Chun-Hong Fang
Chinese Medical Journal|March 28, 2009
Maximizing benefit of drug-eluting stent by direct coronary stenting because of further reduction of inflammatory responseJian-Jun Li, Run-Lin Gao
Science Bulletin|June 26, 2026
Lipoprotein(a): a therapeutic target in waiting? Evidently, evidence-basedRui-Xiang Zeng, Jian-Jun Li
Medical Hypotheses|June 15, 2004
Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosisJian-Jun Li, Chun-Hong Fang
Clinical Chemistry|August 27, 2005
Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable anginaJian-Jun Li, Chun-Hong Fang
Chronic Diseases and Translational Medicine|October 25, 2017
Clinical considerations of lipid target and goal in dyslipidemia controlNa-Qiong Wu, Jian-Jun Li
Pageof 83